USA Today · Jul 2026
Mainstream consumer coverage describing FODZYME as an attention-getting option for people with IBS/FODMAP sensitivities and explaining how the powder works on food before digestion.
Patent-pending enzymes to break down common dietary triggers
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Kiwi Biosciences is the company behind FODZYME®, a patent-pending enzyme powder for FODMAP-related digestive symptoms. It sells primarily as a consumer health supplement, with additional clinician/provider distribution and support resources.
Primary product
FODZYME®
Founded
2020
Headquarters
Cambridge, Massachusetts, United States
Team size
10-20
Work style
Flexible
Industry
Biotechnology
Sub-industry
digestive health enzyme supplements
Offices
Cambridge, Massachusetts, United States
Somerville, Massachusetts, United States
Boston, Massachusetts, United States
Business model
direct-to-consumer ecommerce
subscription
clinician/provider referral
wholesale to providers
marketplace retail via Amazon
B2B clinician support program
Funding
People & investors
Leadership
Co-Founder & CEO
David Hachuel Gurska
Co-Founder & COO
Head of Clinical Strategy & Partnerships
Head of Customer Experience & Retention
Founding Scientist
Work & culture
Mission-driven, science-backed, customer-support-heavy, and collaborative with clinicians. Public hiring and help-center materials suggest a small, fast-moving team with a strong emphasis on education, transparency, and practical customer support.
Work style
Flexible
Compensation
Public job posts emphasize benefits such as 401(k), health insurance, education stipend, flexible vacation, and remote/flexible roles; I did not find reliable public salary bands.
Benefits
30-day risk-free guarantee
free U.S. shipping
HSA/FSA eligibility
subscription savings
first-order discounts via quiz or clinician referral
dietitian onboarding / consultation support
bulk discounts
provider samples
Product & market
Pricing
Premium consumer supplement sold as one-time purchase or subscription, with clinician discounts, quiz discounts, and provider/wholesale channels.
Differentiators
- —powder is mixed directly onto food instead of swallowed in a capsule
- —targets fructan, GOS, and lactose directly
- —includes fructan hydrolase, a rare/first-commercially-available fructan-targeting enzyme
- —peer-reviewed clinical and in-vitro evidence is publicly cited
- —certified low-FODMAP by Monash University and FODMAP Friendly
- —clinician support and referral programs
Technology
Shopify
Cloudflare
Amazon Web Services
Google Analytics
Klaviyo
Gorgias
Google Search Console
jQuery
Google Fonts
Meta/Facebook ads
Customers
people with IBS
people with FODMAP sensitivities
people with lactose, fructan, or GOS intolerance
dietitians and gastroenterologists
clinician-referred patients
direct-to-consumer supplement shoppers
Competitors
Microbiome Labs FODMATE
Beano
Digestive Advantage
Enzymedica FODzyme
Casa de Sante enzyme products
Scale & contact
Estimated revenue
≈$1.2M ARR (2024 estimate)
Estimated monthly visits
126K
Traffic estimate as of Jun 2026
Latest news
El Paso Times · Jul 2026
Another recent consumer article describing the product mechanism, common trigger foods, and why the powder format differs from capsule-based enzyme supplements.
A Gutsy Girl · Jul 2026
A detailed product review discussing FODZYME's fructan/GOS/lactose targeting, powder delivery, and comparison with other digestive enzyme options.
FODZYME clinician blog · Jun 2026
Company clinician blog summarizing digestive disease conference takeaways and highlighting newer clinical evidence and the product’s differentiation around fructan hydrolase.
TechCrunch · Oct 2021
Seed-round announcement covering the founders, early product-market positioning, customer traction at the time, and the 2021 financing round.
Jobs and careers at Kiwi Biosciences
0 jobs at Kiwi Biosciences
No open positions
Check back later for new openings